In today’s recent session, 0.77 million shares of the Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have been traded, and its beta is 0.98. Most recently the company’s share price was $3.28, and it changed around -$0.25 or -7.22% from the last close, which brings the market valuation of the company to $506.74M. MREO at last check was trading at a discount to its 52-week high of $5.02, offering almost -53.05% off that amount. The share price’s 52-week low was $1.86, which indicates that the recent value has risen by an impressive 43.29% since then. We note from Mereo Biopharma Group Plc ADR’s average daily trading volume that its 10-day average is 0.85 million shares, with the 3-month average coming to 772.49K.
Mereo Biopharma Group Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended MREO as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Mereo Biopharma Group Plc ADR is expected to report earnings per share of 0.01 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO has been showing red trend so far today with a performance of -7.22% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.29 on recent trading dayincreased the stock’s daily price by 23.54%. The company’s shares are currently up 41.77% year-to-date, but still down -23.48% over the last five days. On the other hand, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -29.11% down in the 30-day period. We can see from the shorts that 4.57 million shares have been sold at a short interest cover period of 7.45 day(s).
The consensus price target as assigned by Wall Street analysts is $7.5, which translates to bulls needing to increase their stock price by 56.27% from its current value. Analyst projections state that MREO is forecast to be at a low of $4 and a high of $8.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
The year-over-year growth rate is expected to be 43.61%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 11.37M in revenue for the current quarter. 5 analysts expect Mereo Biopharma Group Plc ADR to make 6.59M in revenue for the current ending quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 41.78%.
MREO Dividends
Mereo Biopharma Group Plc ADR’s next quarterly earnings report is expected to be released on 2024-Nov-12.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.02% of Mereo Biopharma Group Plc ADR shares, and 68.30% of them are in the hands of institutional investors. The stock currently has a share float of 69.00%. Mereo Biopharma Group Plc ADR stock is held by 86.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 2.1859% of the shares, which is about 15.31 million shares worth $55.11 million.
ADAGE CAPITAL PARTNERS GP, L.L.C., with 1.6838% or 11.79 million shares worth $42.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
